TY - JOUR
T1 - Molecular profiling in the treatment of colorectal cancer
T2 - Focus on regorafenib
AU - Yan, Yiyi
AU - Grothey, Axel
N1 - Publisher Copyright:
© 2015 Yan and Grothey.
PY - 2015/10/15
Y1 - 2015/10/15
N2 - Metastatic colorectal cancer (mCRC) is a highly heterogeneous disease. Its treatment outcome has been significantly improved over the last decade with the incorporation of biological targeted therapies, including anti-EGFR antibodies, cetuximab and panitumumab, and VEGF inhibitors, bevacizumab, ramucirumab, and aflibercept. The identification of predictive biomarkers has further improved the survival by accurately selecting patients who are most likely to benefit from these treatments, such as RAS mutation profiling for EGFR antibodies. Regorafenib is a multikinase inhibitor currently used as late line therapy for mCRC. The molecular and genetic markers associated with regorafenib treatment response are yet to be characterized. Here, we review currently available clinical evidence of mCRC molecular profiling, such as RAS, BRAF, and MMR testing, and its role in targeted therapies with special focus on regorafenib treatment.
AB - Metastatic colorectal cancer (mCRC) is a highly heterogeneous disease. Its treatment outcome has been significantly improved over the last decade with the incorporation of biological targeted therapies, including anti-EGFR antibodies, cetuximab and panitumumab, and VEGF inhibitors, bevacizumab, ramucirumab, and aflibercept. The identification of predictive biomarkers has further improved the survival by accurately selecting patients who are most likely to benefit from these treatments, such as RAS mutation profiling for EGFR antibodies. Regorafenib is a multikinase inhibitor currently used as late line therapy for mCRC. The molecular and genetic markers associated with regorafenib treatment response are yet to be characterized. Here, we review currently available clinical evidence of mCRC molecular profiling, such as RAS, BRAF, and MMR testing, and its role in targeted therapies with special focus on regorafenib treatment.
KW - Metastatic colon cancer
KW - Molecular profiling
KW - Regorafenib
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=84944746471&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84944746471&partnerID=8YFLogxK
U2 - 10.2147/OTT.S79145
DO - 10.2147/OTT.S79145
M3 - Review article
AN - SCOPUS:84944746471
SN - 1178-6930
VL - 8
SP - 2949
EP - 2957
JO - OncoTargets and Therapy
JF - OncoTargets and Therapy
ER -